FDA Alert: Atezolizumab/Paclitaxel Ineffective for Triple-Negative Breast Cancer

The FDA has issued an alert regarding the combination of atezolizumab (Tecentriq®, Genentech) and paclitaxel for the treatment of patients with previously untreated, inoperable locally advanced or metastatic triple-negative breast cancer (TNBC). In addition to being ineffective, atezolizumab/paclitaxel can negatively impact overall survival. While atezolizumab/paclitaxel is not approved for the treatment of breast cancer, atezolizumab in combination with paclitaxel protein-bound particles, also ...
Continue reading

Paclitaxel for Stage IV Anal Cancer

Even though anal cancer only accounts for 2.7% of all digestive malignancies, with only 8,300 new cases diagnosed each year, its incidence has been rising over the last 30 years. This is due to a variety of factors, including human papillomavirus (HPV) infection, cigarette smoking, and infection with human immunodeficiency virus (HIV), among others. The treatment for locoregional squamous cell cancer of the anal canal is well established, consisting of the combined therapy of 5-fluorouracil (5-F...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.